Advanced Heart Failure and End-Stage Heart Failure: Does a Difference Exist
- PMID: 31683887
- PMCID: PMC6963179
- DOI: 10.3390/diagnostics9040170
Advanced Heart Failure and End-Stage Heart Failure: Does a Difference Exist
Abstract
Advanced heart failure (AdHF) represents a challenging aspect of heart failure patients. Because of worsening clinical symptoms, high rates of re-hospitalization and mortality, AdHF represents an unstable condition where standard treatments are inadequate and additional interventions must be applied. A heart transplant is considered the optimal therapy for AdHF, but the great problem linked to the scarcity of organs and long waiting lists have led to the use of mechanical circulatory support with ventricular-assist device (VAD) as a destination therapy. VAD placement improves the prognosis, functional status, and quality of life of AdHF patients, with high rates of survival at 1 year, similar to transplant. However, the key element is to select the right patient at the right moment. The complete assessment must include a careful clinical evaluation, but also take into account psychosocial factors that are of crucial importance in the out-of-hospital management. It is important to distinguish between AdHF and end-stage HF, for which advanced therapy interventions would be unreasonable due to severe and irreversible organ damage and, instead, palliative care should be preferred to improve quality of life and relief of suffering. The correct selection of patients represents a great issue to solve, both ethically and economically.
Keywords: HLM classification; advanced heart failure; end stage heart failure; orthotopic heart transplant; ventricular assist device.
Conflict of interest statement
The authors declare no conflict of interests.
Figures
References
-
- Hjalmarson A., Goldstein S., Fagerberg B., Wedel H., Waagstein F., Kjekshus J., Wikstrand J., Westergren G., Thimell M., El Allaf D., et al. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet. 1999;353:2001–2007. - PubMed
-
- The Criteria Committee of the New York Heart Association . Functional Capacity and Objective Assessment. In: Dolgin M., editor. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th ed. Little, Brown and Company; Boston, MA, USA: 1994. pp. 253–255.
-
- Yancy C.W., Jessup M., Bozkurt B., Butler J., Casey D.E., Drazner M.H., Fonarow G.C., Geraci S.A., Horwich T., Januzzi J.L., et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. J. Am. Coll. Cardiol. 2017;70:776–803. doi: 10.1016/j.jacc.2017.04.025. - DOI - PubMed
-
- Lloyd-Jones D., Adams R., Carnethon M., De Simone G., Ferguson T.B., Flegal K., Ford E., Furie K., Go A., Greenlund K., et al. Heart disease and stroke statistics-2009 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119:e21–e181. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
